FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	20540
wasiiiigton,	D.C.	20049

ger subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
orm 5	
0 200	

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer sub Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Pascoe Richard W				2. Issuer Name and Ticker or Trading Symbol KEMPHARM, INC [KMPH]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
	MPHARM,	,	(Middle) D. SUITE 103		3. Date of Earliest Transaction (Month/Day/Year) 01/09/2023							below)			Other (specify below)			
(Street)	RATION F	L	34747 (Zip)	4.							6. Liı	ne) X	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			е	Execution Date,		Code (Instr.		ed (A) or str. 3, 4 and	or 5. Amour Securities Beneficia Owned F. Reported		s Form ally (D) o ollowing (I) (Ir		Direct Indirect Estr. 4)	7. Nature of ndirect Beneficial Ownership				
							Code	v	Amount	(A) c (D)	Price	т	ransaction Instr. 3 ar	ion(s)			nstr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Security or Exercise (Month/Day/Year) if any		Execution Date,	Code (Instr.		Derivative I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Share	s		(Instr. 4)			
Stock Option (right to buy)	\$4.54	01/09/2023		A		700,000		(1)	0	1/08/2033	Common Stock	700,00	0	\$0	700,00	0	D	

Explanation of Responses:

1. Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 6, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.

> /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Richard W. 01/11/2023 Pascoe

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.